Literature DB >> 23229688

Neuropathological changes in the nucleus basalis in schizophrenia.

M R Williams1, R Marsh, C D Macdonald, J Jain, R K B Pearce, S R Hirsch, O Ansorge, S M Gentleman, M Maier.   

Abstract

The nucleus basalis has not been examined in detail in severe mental illness. Several studies have demonstrated decreases in glia and glial markers in the cerebral cortex in schizophrenia, familial bipolar disorder and recurrent depression. Changes in neocortical neuron size and shape have also been reported. The nucleus basalis is a collection of large cholinergic neurons in the basal forebrain receiving information from the midbrain and limbic system, projecting to the cortex and involved with attention, learning and memory, and receives regulation from serotonergic inputs. Forty-one cases aged 41-60 years with schizophrenia or major depressive disorder with age-matched controls were collected. Formalin-fixed paraffin-embedded coronal nucleus basalis sections were histologically stained for oligodendrocyte identification with cresyl-haematoxylin counterstain, for neuroarchitecture with differentiated cresyl violet stain and astrocytes were detected by glial fibrillary acid protein immunohistochemistry. Cell density and neuroarchitecture were measured using Image Pro Plus. There were larger NB oval neuron soma in the combined schizophrenia and major depression disorder groups (p = 0.038), with no significant change between controls and schizophrenia and major depression disorder separately. There is a significant reduction in oligodendrocyte density (p = 0.038) in the nucleus basalis in schizophrenia. The ratio of gemistocytic to fibrillary astrocytes showed a greater proportion of the former in schizophrenia (18.1 %) and major depressive disorder (39.9 %) than in controls (7.9 %). These results suggest glial cell abnormalities in the nucleus basalis in schizophrenia possibly leading to cortical-limbic disturbance and subcortical dysfunction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229688     DOI: 10.1007/s00406-012-0387-7

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  87 in total

1.  Projections from the nucleus accumbens to cholinergic neurons of the ventral pallidum: a correlated light and electron microscopic double-immunolabeling study in rat.

Authors:  L Záborszky; W E Cullinan
Journal:  Brain Res       Date:  1992-01-20       Impact factor: 3.252

2.  Cholinergic and non-cholinergic neurons of cat basal forebrain project to reticular and mediodorsal thalamic nuclei.

Authors:  M Steriade; A Parent; D Paré; Y Smith
Journal:  Brain Res       Date:  1987-04-07       Impact factor: 3.252

Review 3.  The nucleus basalis magnocellularis cholinergic system: one hundred years of progress.

Authors:  G L Wenk
Journal:  Neurobiol Learn Mem       Date:  1997-03       Impact factor: 2.877

4.  Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  B Dean; M McLeod; D Keriakous; J McKenzie; E Scarr
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

5.  Neuropathology of epilepsy and psychosis: the contributions of J.A.N. Corsellis.

Authors:  Burkhard S Kasper; David C Taylor; Dieter Janz; Ekkehard M Kasper; Michael Maier; Matthew R Williams; Timothy J Crow
Journal:  Brain       Date:  2010-09-03       Impact factor: 13.501

6.  Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Oliver Freudenreich; Lawrence Herz; Thilo Deckersbach; A Eden Evins; David C Henderson; Corinne Cather; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

7.  Changes in cortical thickness in the frontal lobes in schizophrenia are a result of thinning of pyramidal cell layers.

Authors:  M R Williams; R Chaudhry; S Perera; R K B Pearce; S R Hirsch; O Ansorge; M Thom; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-19       Impact factor: 5.270

8.  The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in the rat.

Authors:  J D Stoehr; S L Mobley; D Roice; R Brooks; L M Baker; R G Wiley; G L Wenk
Journal:  Neurobiol Learn Mem       Date:  1997-05       Impact factor: 2.877

9.  A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia.

Authors:  Onder Tuğal; Kâzm M Yazici; A Elif Anil Yağcioğlu; Ahmet Göğüş
Journal:  Int J Neuropsychopharmacol       Date:  2004-01-23       Impact factor: 5.176

10.  Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium.

Authors:  Natalya A Uranova; Victor M Vostrikov; Diana D Orlovskaya; Valentina I Rachmanova
Journal:  Schizophr Res       Date:  2004-04-01       Impact factor: 4.939

View more
  12 in total

1.  Impact of lifestyle in severe psychiatric disorders and brain morphology.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-09       Impact factor: 5.270

2.  The neurobiology of transition to psychosis: clearing the cache.

Authors:  Lena Palaniyappan; Tushar Das; Kara Dempster
Journal:  J Psychiatry Neurosci       Date:  2017-09       Impact factor: 6.186

Review 3.  (Micro)Glia as Effectors of Cortical Volume Loss in Schizophrenia.

Authors:  Allyson P Mallya; Ariel Y Deutch
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

Review 4.  Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease.

Authors:  Alan King Lun Liu; Raymond Chuen-Chung Chang; Ronald K B Pearce; Steve M Gentleman
Journal:  Acta Neuropathol       Date:  2015-01-30       Impact factor: 17.088

Review 5.  Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review.

Authors:  M O Trépanier; K E Hopperton; R Mizrahi; N Mechawar; R P Bazinet
Journal:  Mol Psychiatry       Date:  2016-06-07       Impact factor: 15.992

Review 6.  The Importance of Non-neuronal Cell Types in hiPSC-Based Disease Modeling and Drug Screening.

Authors:  David M Gonzalez; Jill Gregory; Kristen J Brennand
Journal:  Front Cell Dev Biol       Date:  2017-12-19

Review 7.  Myelination of parvalbumin interneurons: a parsimonious locus of pathophysiological convergence in schizophrenia.

Authors:  J Stedehouder; S A Kushner
Journal:  Mol Psychiatry       Date:  2016-09-20       Impact factor: 15.992

8.  Correlations between physical activity and neurocognitive domain functions in patients with schizophrenia: a cross-sectional study.

Authors:  Yusuke Kurebayashi; Junichi Otaki
Journal:  BMC Psychiatry       Date:  2017-01-05       Impact factor: 3.630

9.  Serotonergic innervation of the amygdala is increased in autism spectrum disorder and decreased in Williams syndrome.

Authors:  C H Lew; K M Groeniger; K L Hanson; D Cuevas; D M Z Greiner; B Hrvoj-Mihic; U Bellugi; C M Schumann; K Semendeferi
Journal:  Mol Autism       Date:  2020-02-05       Impact factor: 7.509

10.  Fibrillary astrocytes are decreased in the subgenual cingulate in schizophrenia.

Authors:  Matthew Williams; Ronald K B Pearce; Steven R Hirsch; Olaf Ansorge; Maria Thom; Michael Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-12-29       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.